Downstream processing of Irbesartan (cas 138402-11-6) nanocrystalline suspension and mini-tablet development – Part II
-
Add time:08/24/2019 Source:sciencedirect.com
The objectives of this study were to evaluate the impact of formulation variables on the drying of nanocrystalline suspensions either via bead layering or spray granulation and develop mini-tablets from the dried nanocrystalline powders. Irbesartan (cas 138402-11-6) (crystalline Form B), a poorly soluble drug substance was chosen as a model compound. An optimized irbesartan nanocrystalline suspension with a mean particle size of 300 nm was utilized for the downstream processing. Irbesartan nanocrystalline suspension was dried either by layering onto the microcrystalline cellulose beads (i.e. 200 or 500 µm) or by granulation (mannitol or microcrystalline cellulose as substrates) at two different drug loadings (i.e. 10% or 30% w/w). Smaller size beads layered with nanocrystals resulted in faster dissolution profiles compared to larger size beads at both the studied drug loadings (i.e. 10 and 30% w/w). Mannitol granules containing irbesartan nanocrystals resulted in faster dissolution profiles compared to microcrystalline cellulose granules. Microcrystalline cellulose beads and mannitol granules containing irbesartan nanocrystals (i.e. 30% w/w drug loading) were further compressed into mini-tablets. Mini-tablets retained fast drug dissolution characteristics of the dried powders. The results from this study indicated that the spray granulation is a superior drying approach compared to bead layering for drying of irbesartan nanocrystalline suspension and mini-tablet development.
We also recommend Trading Suppliers and Manufacturers of Irbesartan (cas 138402-11-6). Pls Click Website Link as below: cas 138402-11-6 suppliers
Prev:ReviewShould we add atorvastatin to Irbesartan (cas 138402-11-6) for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials
Next:Irbesartan (cas 138402-11-6) desmotropes: Solid-state characterization, thermodynamic study and dissolution properties) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with Irbesartan (cas 138402-11-6) in a rat model of diabetic nephropathy09/01/2019
- Original ArticleChronomodulated drug delivery system of Irbesartan (cas 138402-11-6): Formulation and development using Desing of Experiment (DoE)08/31/2019
- Irbesartan (cas 138402-11-6) attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway08/30/2019
- Exploring the interactions of Irbesartan (cas 138402-11-6) and Irbesartan (cas 138402-11-6)–2-hydroxypropyl-β-cyclodextrin complex with model membranes08/29/2019
- Original ArticleTargeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by Irbesartan (cas 138402-11-6) to ameliorate doxorubicin-induced hepatotoxicity☆08/28/2019
- The thermal decomposition mechanism of Irbesartan (cas 138402-11-6)08/27/2019
- Immunopharmacology and inflammationSuppressive effects of type I angiotensin receptor antagonists, candesartan and Irbesartan (cas 138402-11-6) on allergic asthma08/26/2019
- Irbesartan (cas 138402-11-6) desmotropes: Solid-state characterization, thermodynamic study and dissolution properties08/25/2019
- ReviewShould we add atorvastatin to Irbesartan (cas 138402-11-6) for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials08/23/2019
-
Health and Chemical more >
-
Related Products